Drug Type Antibody drug conjugate (ADC) |
Synonyms Lifastuzumab vedotin (USAN/INN), ANTI-NAPI2B, DNIB-0600A + [5] |
Target |
Action inhibitors |
Mechanism NaPi-2b inhibitors(Sodium-dependent phosphate transport protein 2B inhibitors), Tubulin inhibitors |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11238 | Lifastuzumab vedotin | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Platinum-Resistant Ovarian Carcinoma | Phase 2 | United States | 06 Feb 2014 | |
Platinum-Resistant Ovarian Carcinoma | Phase 2 | Belgium | 06 Feb 2014 | |
Platinum-Resistant Ovarian Carcinoma | Phase 2 | Canada | 06 Feb 2014 | |
Platinum-Resistant Ovarian Carcinoma | Phase 2 | France | 06 Feb 2014 | |
Platinum-Resistant Ovarian Carcinoma | Phase 2 | Poland | 06 Feb 2014 | |
Platinum-Resistant Ovarian Carcinoma | Phase 2 | Spain | 06 Feb 2014 | |
Platinum-Resistant Ovarian Carcinoma | Phase 2 | United Kingdom | 06 Feb 2014 | |
Fallopian Tube Carcinoma | Phase 2 | United States | - | |
Fallopian Tube Carcinoma | Phase 2 | Belgium | - | |
Fallopian Tube Carcinoma | Phase 2 | Canada | - |